140 related articles for article (PubMed ID: 36735530)
21. Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity.
Fahey CC; Gracie TJ; Johnson DB
Expert Rev Anticancer Ther; 2023 Jul; 23(7):673-683. PubMed ID: 37194222
[TBL] [Abstract][Full Text] [Related]
22. Immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors.
Byrne MM; Lucas M; Pai L; Breeze J; Parsons SK
Eur J Haematol; 2021 Dec; 107(6):650-657. PubMed ID: 34453348
[TBL] [Abstract][Full Text] [Related]
23. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
Cancer Immunol Immunother; 2023 Nov; 72(11):3581-3591. PubMed ID: 37540262
[TBL] [Abstract][Full Text] [Related]
24. Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy.
Li A; May SB; La J; Martens KL; Amos CI; Flowers CR; Do NV; Brophy MT; Chitalia V; Ravid K; Gaziano JM; Fillmore NR
Am J Hematol; 2023 Aug; 98(8):1214-1222. PubMed ID: 37161855
[TBL] [Abstract][Full Text] [Related]
25. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
26. Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
Oppolzer IA; Riester J; Büttner R; Burger M; Schnabel MJ
Int Urol Nephrol; 2023 Aug; 55(8):1943-1949. PubMed ID: 37271776
[TBL] [Abstract][Full Text] [Related]
27. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
Alserawan L; Anguera G; Zamora Atenza C; Serra López J; Martínez-Martínez L; Riudavets Melià M; Sullivan I; Barba Joaquin A; Majem Tarruella M; Vidal S
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293498
[TBL] [Abstract][Full Text] [Related]
28. Chronic gastrointestinal immune-related adverse events in patients exposed to immune checkpoint inhibitors.
Jeay M; Carbonnel F; Robert C; Mussini C; Bellanger C; Meyer A
Clin Res Hepatol Gastroenterol; 2024 Apr; 48(4):102311. PubMed ID: 38430989
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes.
Yu K; Mathew A; Abraham F; Amin R; Kono M; Overman M; Zhao D; Khan A; Khan MA; Thomas AS; Wang Y
Ann Gastroenterol; 2022; 35(5):514-521. PubMed ID: 36061157
[TBL] [Abstract][Full Text] [Related]
30. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
[TBL] [Abstract][Full Text] [Related]
31. Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
Albandar HJ; Fuqua J; Albandar JM; Safi S; Merrill SA; Ma PC
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33673446
[TBL] [Abstract][Full Text] [Related]
32. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
[TBL] [Abstract][Full Text] [Related]
33. Relationship between immune-related adverse events and treatment effectiveness in extensive disease small cell lung cancer.
Yokoo K; Kitamura Y; Suzuki K; Morikawa K; Sawai T; Honda H; Kudo S; Yamada G
Thorac Cancer; 2023 Aug; 14(23):2251-2258. PubMed ID: 37365145
[TBL] [Abstract][Full Text] [Related]
34. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
35. Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival.
Alomari M; Al Ashi S; Chadalavada P; Khazaaleh S; Covut F; Al Momani L; Elkafrawy A; Padbidri V; Funchain P; Campbell D; Romero-Marrero C
Gastroenterology Res; 2022 Apr; 15(2):56-66. PubMed ID: 35572476
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
Schmitt C; Hoefsmit EP; Fangmeier T; Kramer N; Kabakci C; Vera González J; Versluis JM; Compter A; Harrer T; Mijočević H; Schubert S; Hundsberger T; Menzies AM; Scolyer RA; Long GV; French LE; Blank CU; Heinzerling LM
Cancer Immunol Immunother; 2023 Nov; 72(11):3475-3489. PubMed ID: 37606856
[TBL] [Abstract][Full Text] [Related]
37. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
38. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
39. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors.
de Malet A; Antoni G; Collins M; Soularue E; Marthey L; Vaysse T; Coutzac C; Chaput N; Mateus C; Robert C; Carbonnel F
Eur J Cancer; 2019 Jan; 106():106-114. PubMed ID: 30476730
[TBL] [Abstract][Full Text] [Related]
40. Association between immune-related adverse event timing and treatment outcomes.
Hsiehchen D; Naqash AR; Espinoza M; Von Itzstein MS; Cortellini A; Ricciuti B; Owen DH; Laharwal M; Toi Y; Burke M; Xie Y; Gerber DE
Oncoimmunology; 2022; 11(1):2017162. PubMed ID: 35003896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
